托法替尼在儿童风湿性疾病中的研究进展

doi:10.7499/j.issn.1008-8830.2201081

摘要
图/表
参考文献(41)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (577 KB) [HTML]
输出: BibTeX | EndNote (RIS) 背景资料

摘要托法替尼是一种Janus激酶抑制剂，能够阻断Janus激酶和相关的信号转导及转录激活因子信号转导通路，减少多种细胞因子的生成与释放，具有治疗多种风湿病的潜力，其优点是起效快、能减少对糖皮质激素的依赖和相关不良事件。托法替尼在成人患者中的治疗作用已被证实，近年来已越来越多应用于儿童患者中，该文就托法替尼在儿童风湿病中的临床应用作一综述。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	周仕海
	熊亚群
	陈雅

关键词 ：风湿性疾病, JAK-STAT通路, 托法替尼, 儿童

Abstract：Tofacitinib is a Janus kinase inhibitor and can block the Janus kinase-signal transducer and activator of transcription signal transduction pathway and reduce the production and release of a variety of cytokines. It has great potential in the treatment of various rheumatic diseases with a rapid onset of action and can reduce corticosteroid dependence and related adverse events. The therapeutic effect of tofacitinib in adult patients has been confirmed, and it has been increasingly used in pediatric patients in recent years. This article reviews the clinical application of tofacitinib in the treatment of pediatric autoimmune diseases.

Key words： Rheumatic disease Janus kinase-signal transducer and activator of transcription signaling pathway Tofacitinib Child

收稿日期: 2022-01-20

通讯作者: 罗平，女，主管药师。Email：luoping1011@126.com。 E-mail: luoping1011@126.com

作者简介: 周仕海，男，硕士研究生，主管药；

引用本文:

周仕海,熊亚群,陈雅. 托法替尼在儿童风湿性疾病中的研究进展[J]. 中国当代儿科杂志, 2022, 24(4): 447-453.

ZHOU Shi-Hai,XIONG Ya-Qun,CHEN Ya. Recent research on tofacitinib in the treatment of pediatric rheumatic diseases[J]. CJCP, 2022, 24(4): 447-453.

链接本文:

http://www.zgddek.com/CN/10.7499/j.issn.1008-8830.2201081 或 http://www.zgddek.com/CN/Y2022/V24/I4/447

	Mok CC. The Jakinibsin systemic lupus erythematosus: progress and prospects[J]. Expert OpinInvestig Drugs, 2019, 28(1): 85-92. PMID: 30462559. DOI: 10.1080/13543784.2019.1551358.
	Tzeng HT, Chyuan IT, Lai JH. Targeting the JAK-STAT pathway in autoimmune diseases and cancers: a focus on molecular mechanisms and therapeutic potential[J]. Biochem Pharmacol, 2021, 193: 114760. PMID: 34492272. DOI: 10.1016/j.bcp.2021.114760.
	Xin P, Xu X, Deng C, et al. The role of JAK/STAT signaling pathway and its inhibitors in diseases[J]. Int Immunopharmacol, 2020, 80: 106210. PMID: 31972425. DOI: 10.1016/j.intimp.2020.106210.
	Kahn JS, Deverapalli SC, Rosmarin DM. JAK-STAT signaling pathway inhibition: a role for treatment of discoid lupus erythematosus and dermatomyositis[J]. Int J Dermatol, 2018, 57(8): 1007-1014. PMID: 29873082. DOI: 10.1111/ijd.14064.
	Salas A, Hernandez-Rocha C, Duijvestein M, et al. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(6): 323-337. PMID: 32203403. DOI: 10.1038/s41575-020-0273-0.
	Liu S, Ma H, Zhang H, et al. Recent advances on signaling pathways and their inhibitors in rheumatoid arthritis[J]. Clin Immunol, 2021, 230: 108793. PMID: 34242749. DOI: 10.1016/j.clim.2021.108793.
	Crispino N, Ciccia F. JAK/STAT pathway and nociceptive cytokine signalling in rheumatoid arthritis and psoriatic arthritis[J]. Clin Exp Rheumatol, 2021, 39(3): 668-675. PMID: 33200731.
	Jamilloux Y, El Jammal T, Vuitton L, et al. JAK inhibitors for the treatment of autoimmune and inflammatory diseases[J]. Autoimmun Rev, 2019, 18(11): 102390. PMID: 31520803. DOI: 10.1016/j.autrev.2019.102390.
	Fragoulis GE, McInnes IB, Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis[J]. Rheumatology (Oxford), 2019, 58(Suppl 1): i43-i54. PMID: 30806709. PMCID: PMC6390879. DOI: 10.1093/rheumatology/key276.
	Yu B, Wang X, Yang Y, et al. Evaluation of tofacitinib citrate bioequivalence based on pharmacokinetic parameters in healthy Chinese subjects[J]. Int J Clin Pharmacol Ther, 2021, 59(4): 343-352. PMID: 33433317. DOI: 10.5414/CP203751.
	Ruperto N, Brunner HI, Zuber Z, et al. Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study[J]. Pediatr Rheumatol Online J, 2017, 15(1): 86. PMID: 29282090. PMCID: PMC5745974. DOI: 10.1186/s12969-017-0212-y.
	Miyoshi S, Krishnaswami S, Toyoizumi S, et al. Phase 1 dose-escalation study to evaluate the pharmacokinetics, safety, and tolerability of tofacitinib in Japanese healthy volunteers[J]. Clin Pharmacol Drug Dev, 2020, 9(1): 11-20. PMID: 31713350. PMCID: PMC7003739. DOI: 10.1002/cpdd.741.
	lvaro-Gracia JM, García-Llorente JF, Valderrama M, et al. Update on the safety profile of tofacitinib in rheumatoid arthritis from clinical trials to real-world studies: a narrative review[J]. Rheumatol Ther, 2021, 8(1): 17-40. PMID: 33245555. PMCID: PMC7991042. DOI: 10.1007/s40744-020-00258-9.
	El Jammal T, Sève P, Gerfaud-Valentin M, et al. State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis[J]. Expert Opin Pharmacother, 2021, 22(2): 205-218. PMID: 32967471. DOI: 10.1080/14656566.2020.1822325.
	Caporali R, Zavaglia D. Real-world experience with tofacitinib for the treatment of rheumatoid arthritis[J]. Clin Exp Rheumatol, 2019, 37(3): 485-495. PMID: 30183607.
	Huang Z, Lee PY, Yao X, et al. Tofacitinib treatment of refractory systemic juvenile idiopathic arthritis[J]. Pediatrics, 2019, 143(5): e20182845. PMID: 30948682. DOI: 10.1542/peds.2018-2845.
	Ruperto N, Brunner HI, Synoverska O, et al. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial[J]. Lancet, 2021, 398(10315): 1984-1996. PMID: 34767764. DOI: 10.1016/S0140-6736(21)01255-1.
	Simakou T, Butcher JP, Reid S, et al. Alopecia areata: a multifactorial autoimmune condition[J]. J Autoimmun, 2019, 98: 74-85. PMID: 30558963. DOI: 10.1016/j.jaut.2018.12.001.
	Afford R, Leung AKC, Lam JM. Pediatric alopecia areata[J]. Curr Pediatr Rev, 2021, 17(1): 45-54. PMID: 32351186. DOI: 10.2174/1573396316666200430084825.
	Sterkens A, Lambert J, Bervoets A. Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options[J]. Clin Exp Med, 2021, 21(2): 215-230. PMID: 33386567. DOI: 10.1007/s10238-020-00673-w.
	Putterman E, Castelo-Soccio L. Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis[J]. J Am Acad Dermatol, 2018, 78(6): 1207-1209.e1. PMID: 29754888. DOI: 10.1016/j.jaad.2018.02.031.
	Craiglow BG, Liu LY, King BA. Tofacitinib for the treatment of alopecia areata and variants in adolescents[J]. J Am Acad Dermatol, 2017, 76(1): 29-32. PMID: 27816292. DOI: 10.1016/j.jaad.2016.09.006.
	Dai YX, Chen CC. Tofacitinib therapy for children with severe alopecia areata[J]. J Am Acad Dermatol, 2019, 80(4): 1164-1166. PMID: 30630026. DOI: 10.1016/j.jaad.2018.12.041.
	Jerjen R, Meah N, Trindade de Carvalho L, et al. Treatment of alopecia areata in pre-adolescent children with oral tofacitinib: a retrospective study[J]. Pediatr Dermatol, 2021, 38(1): 103-108. PMID: 33099833. DOI: 10.1111/pde.14422.
	DeWane ME, Waldman R, Lu J. Dermatomyositis: clinical features and pathogenesis[J]. J Am Acad Dermatol, 2020, 82(2): 267-281. PMID: 31279808. DOI: 10.1016/j.jaad.2019.06.1309.
	Moneta GM, Pires Marafon D, Marasco E, et al. Muscle expression of type I and type II interferons is increased in juvenile dermatomyositis and related to clinical and histologic features[J]. Arthritis Rheumatol, 2019, 71(6): 1011-1021. PMID: 30552836. DOI: 10.1002/art.40800.
	Kim H. Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy[J]. Curr Opin Rheumatol, 2021, 33(5): 371-377. PMID: 34230439. DOI: 10.1097/BOR.0000000000000816.
	Sabbagh S, Almeida de Jesus A, Hwang S, et al. Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib[J]. Brain, 2019, 142(11): e59. PMID: 31603187. PMCID: PMC6821280. DOI: 10.1093/brain/awz293.
	Yu Z, Wang L, Quan M, et al. Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review[J]. Rheumatology (Oxford), 2021, 60(4): 1700-1707. PMID: 33024992. DOI: 10.1093/rheumatology/keaa558.
	Chung MP, Richardson C, Kirakossian D, et al. Calcinosis biomarkers in adult and juvenile dermatomyositis[J]. Autoimmun Rev, 2020, 19(6): 102533. PMID: 32234404. PMCID: PMC7225028. DOI: 10.1016/j.autrev.2020.102533.
	Huber AM. Juvenile idiopathic inflammatory myopathies[J]. Pediatr Clin North Am, 2018, 65(4): 739-756. PMID: 30031496. DOI: 10.1016/j.pcl.2018.04.006.
	S?zeri B, Demir F. A striking treatment option for recalcitrant calcinosis in juvenile dermatomyositis: tofacitinib citrate[J]. Rheumatology (Oxford), 2020, 59(12): e140-e141. PMID: 32754736. DOI: 10.1093/rheumatology/keaa360.
	S?uczanowska-G??bowska S, Ziegler-Krawczyk A, Szumilas K, et al. Role of Janus kinase inhibitors in therapy of psoriasis[J]. J Clin Med, 2021, 10(19): 4307. PMID: 34640327. PMCID: PMC8509829. DOI: 10.3390/jcm10194307.
	Du Y, Jiang S, Cheng L, et al. JAK/STAT and VEGF/PAK1 signaling as emerging targets for topical treatment of psoriasis: a pilot study[J]. Int J Clin Exp Pathol, 2020, 13(12): 3111-3119. PMID: 33425111. PMCID: PMC7791387.
	AlMutairi N, Nour T. Tofacitinib in pediatric psoriasis: an open-label trial to study its safety and efficacy in children[J]. Dermatology, 2020, 236(3): 191-198. PMID: 31665730. DOI: 10.1159/000503062.
	Dolinger MT, Rolfes P, Phan BL, et al. Letter: tofacitinib use for biologic-refractory paediatric inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2019, 50(8): 966-967. PMID: 31591772. DOI: 10.1111/apt.15496.
	Moore H, Dubes L, Fusillo S, et al. Tofacitinib therapy in children and young adults with pediatric-onset medically refractory inflammatory bowel disease[J]. J Pediatr Gastroenterol Nutr, 2021, 73(3): e57-e62. PMID: 34091545. DOI: 10.1097/MPG.0000000000003190.
	Dolinger MT, Spencer EA, Lai J, et al. Dual biologic and small molecule therapy for the treatment of refractory pediatric inflammatory bowel disease[J]. Inflamm Bowel Dis, 2021, 27(8): 1210-1214. PMID: 33125058. DOI: 10.1093/ibd/izaa277.
	Nash P, Kerschbaumer A, D?rner T, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement[J]. Ann Rheum Dis, 2021, 80(1): 71-87. PMID: 33158881. PMCID: PMC7788060. DOI: 10.1136/annrheumdis-2020-218398.
	Onel K, Rumsey DG, Shenoi S. Juvenile idiopathic arthritis treatment updates[J]. Rheum Dis Clin North Am, 2021, 47(4): 545-563. PMID: 34635291. DOI: 10.1016/j.rdc.2021.07.009.
	中华医学会风湿病学分会. 2018中国类风湿关节炎诊疗指南[J]. 中华内科杂志, 2018, 57(4): 242-251. PMID: 29614581. DOI: 10.3760/cma.j.issn.0578-1426.2018.04.004.